Geode Capital Management LLC Has $3.21 Million Stock Holdings in PepGen Inc. (NASDAQ:PEPG)

Geode Capital Management LLC trimmed its holdings in shares of PepGen Inc. (NASDAQ:PEPG) by 1.0% in the third quarter, according to its most recent filing with the SEC. The firm owned 375,325 shares of the company’s stock after selling 3,772 shares during the period. Geode Capital Management LLC owned approximately 1.15% of PepGen worth $3,210,000 as of its most recent filing with the SEC.

Several other large investors also recently modified their holdings of the stock. Janus Henderson Group PLC boosted its position in PepGen by 331.2% in the third quarter. Janus Henderson Group PLC now owns 2,336,516 shares of the company’s stock valued at $20,012,000 after buying an additional 1,794,641 shares in the last quarter. Suvretta Capital Management LLC raised its stake in shares of PepGen by 9.2% during the third quarter. Suvretta Capital Management LLC now owns 1,660,932 shares of the company’s stock worth $14,201,000 after buying an additional 140,000 shares during the last quarter. Walleye Capital LLC acquired a new position in shares of PepGen in the 3rd quarter valued at $519,000. Sofinnova Investments Inc. boosted its holdings in PepGen by 11.4% during the second quarter. Sofinnova Investments Inc. now owns 561,128 shares of the company’s stock worth $8,956,000 after buying an additional 57,504 shares during the last quarter. Finally, Wellington Management Group LLP increased its stake in PepGen by 76.9% in the third quarter. Wellington Management Group LLP now owns 40,517 shares of the company’s stock valued at $346,000 after purchasing an additional 17,618 shares in the last quarter. 58.01% of the stock is currently owned by institutional investors.

PepGen Stock Down 3.9 %

PepGen stock opened at $3.68 on Tuesday. The stock has a market cap of $119.95 million, a P/E ratio of -1.23 and a beta of 1.66. The company’s 50-day moving average price is $4.93 and its two-hundred day moving average price is $9.21. PepGen Inc. has a twelve month low of $2.90 and a twelve month high of $19.30.

Wall Street Analysts Forecast Growth

PEPG has been the topic of several recent analyst reports. Wedbush cut their price objective on PepGen from $19.00 to $12.00 and set an “outperform” rating on the stock in a report on Friday, November 8th. Bank of America lowered PepGen from a “neutral” rating to an “underperform” rating and set a $3.00 price target on the stock. in a research report on Monday, December 16th. Finally, HC Wainwright reiterated a “buy” rating and set a $26.00 price target on shares of PepGen in a report on Friday, November 8th.

PepGen Company Profile

PepGen Inc, a clinical-stage biotechnology company, focuses on the development of oligonucleotide therapeutics for use in the treatment of severe neuromuscular and neurologic diseases. Its lead product candidate is PGN-EDO51, an EDO peptide that is in Phase 2 clinical trial to treat Duchenne muscular dystrophy (DMD) patients.